THERAFLU COLD & SORE THROAT HOT LIQUID OTC
Generic Name and Formulations:
Acetaminophen 325mg, pheniramine maleate 20mg, phenylephrine HCl 10mg; pwd packets; natural lemon flavor; contains sodium 44mg per packet.
Novartis Consumer Health
Indications for THERAFLU COLD & SORE THROAT HOT LIQUID:
Nasal congestion, rhinorrhea, sore throat, fever, headache, minor aches and pains.
Dissolve contents of 1 packet into 8oz hot water; sip while hot. Consume entire drink within 10–15mins. Take every 4 hours; max 6 packets/24hrs.
During or within 14 days of MAOIs. Concomitant other acetaminophen products.
Hepatic dysfunction. Cardiovascular disease. Hypertension. Thyroid disease. Diabetes. GI or GU obstruction. Glaucoma. Asthma. Lower respiratory disorders. Sodium restricted diet. Discontinue if symptoms worsen or persist after 2–7 days. Pregnancy. Nursing mothers.
See Contraindications. Hypertensive crisis with MAOIs. Increased risk of hepatotoxicity with ≥3 alcoholic drinks/day; avoid. β-blockers may increase the pressor effects of sympathomimetics. Antihypertensives antagonized. Increased CNS effects with other CNS depressants.
Analgesic + antihistamine + sympathomimetic.
Drowsiness, anticholinergic effects, nervousness, dizziness, insomnia, excitability in children, hepatotoxicity (overdosage).
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies